Immune thrombocytopenia: Pathophysiologic and clinical update

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 5, 2012, Pages 454-462

  Stasi, Roberto ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

B cells; corticosteroids; immune thrombocytopenia; platelet autoantibodies; splenectomy; T cells; thrombopoietin receptor agonists

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; DANAZOL; DAPSONE; DEXAMETHASONE; ELTROMBOPAG; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; RITUXIMAB; ROMIPLOSTIM; VINCA ALKALOID; AUTOANTIBODY;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CD3+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DYSPEPSIA; FATIGUE; GENE EXPRESSION; HELICOBACTER INFECTION; HELPER CELL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHINOPHARYNGITIS; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VOMITING; BLOOD; IMMUNOLOGY; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTOPENIA;

AUTOANTIBODIES; BLOOD PLATELETS; HUMANS; THROMBOCYTOPENIA;

EID: 84863106330     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1305780     Document Type: Article

References (96)

1. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood: 2009; 113 11 2386 2393
2. Stratton J. R., Ballem P. J., Gernsheimer T., Cerqueira M., Slichter S. J. Platelet destruction in autoimmune thrombocytopenic purpura: kinetics and clearance of indium-111-labeled autologous platelets. J Nucl Med: 1989; 30 5 629 637 (Pubitemid 19140256)
3. Louwes H., Zeinali Lathori O. A., Vellenga E., de Wolf J. T. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med: 1999; 106 4 430 434 (Pubitemid 29190596)
4. Harrington W. J., Minnich V., Hollingsworth J. W., Moore C. V. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med: 1951; 38 1 1 10
5. Shulman N. R., Marder V. J., Weinrach R. S. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci: 1965; 124 2 499 542
6. Sukati H., Watson H. G., Urbaniak S. J., Barker R. N. Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. Blood: 2007; 109 10 4528 4538 (Pubitemid 46743424)
7. McMillan R., Wang L., Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost: 2003; 1 3 485 491
8. Kuwana M., Kaburaki J., Kitasato H., et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood: 2001; 98 1 130 139
9. McMillan R., Lopez-Dee J., Bowditch R. Clonal restriction of platelet-associated anti-GPIIb/IIIa autoantibodies in patients with chronic ITP. Thromb Haemost: 2001; 85 5 821 823 (Pubitemid 32421814)
10. Stockelberg D., Hou M., Jacobsson S., Kutti J., Wadenvik H. Evidence for a light chain restriction of glycoprotein Ib/IX and IIb/IIIa reactive antibodies in chronic idiopathic thrombocytopenic purpura (ITP). Br J Haematol: 1995; 90 1 175 179
11. McMillan R., Longmire R. L., Yelenosky R., Smith R. S., Craddock C. G. Immunoglobulin synthesis in vitro by splenic tissue in idiopathic thrombocytopenic purpura. N Engl J Med: 1972; 286 13 681 684
12. Kuwana M., Okazaki Y., Kaburaki J., Kawakami Y., Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol: 2002; 168 7 3675 3682 (Pubitemid 34250440)
13. Siegel R. S., Rae J. L., Barth S., et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol: 1989; 30 4 206 212 (Pubitemid 19087309)
14. Takahashi R., Sekine N., Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood: 1999; 93 6 1951 1958 (Pubitemid 29128497)
15. Semple J. W., Milev Y., Cosgrave D., et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood: 1996; 87 10 4245 4254 (Pubitemid 26152268)
16. Stasi R., Del Poeta G., Stipa E., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood: 2007; 110 8 2924 2930 (Pubitemid 350006946)
17. Brighton T. A., Evans S., Castaldi P. A., Chesterman C. N., Chong B. H. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood: 1996; 88 1 194 201 (Pubitemid 26230687)
18. Stockelberg D., Hou M., Jacobsson S., Kutti J., Wadenvik H. Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA. Eur J Haematol: 1996; 56 1-2 72 77 (Pubitemid 26075598)
19. Kuwana M., Kaburaki J., Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest: 1998; 102 7 1393 1402 (Pubitemid 28467568)
20. Filion M. C., Proulx C., Bradley A. J., et al. Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells. Blood: 1996; 88 6 2144 2150 (Pubitemid 26307917)
21. Fogarty P. F., Rick M. E., Zeng W., Risitano A. M., Dunbar C. E., Bussel J. B. T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exp Immunol: 2003; 133 3 461 466 (Pubitemid 37046973)
22. Olsson B., Andersson P. O., Jernås M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med: 2003; 9 9 1123 1124 (Pubitemid 37173694)
23. Liu B., Zhao H., Poon M. C., et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol: 2007; 78 2 139 143 (Pubitemid 46058876)
24. Olsson B., Andersson P. O., Jacobsson S., Carlsson L., Wadenvik H. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost: 2005; 93 1 139 144 (Pubitemid 40124268)
25. Catani L., Fagioli M. E., Tazzari P. L., et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol: 2006; 34 7 879 887
26. Kuwana M., Okazaki Y., Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost: 2009; 7 2 322 329
27. Stasi R., Willis F., Shannon M. S., Gordon-Smith E. C. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin North Am: 2009; 23 6 1275 1297
28. Cines D. B., Liebman H., Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol: 2009; 46 1, Suppl 2 S2 S14
29. Zhang W., Nardi M. A., Borkowsky W., Li Z., Karpatkin S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood: 2009; 113 17 4086 4093
30. Nardi M. A., Liu L. X., Karpatkin S. GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia. Proc Natl Acad Sci U S A: 1997; 94 14 7589 7594 (Pubitemid 27345360)
31. Li Z., Nardi M. A., Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood: 2005; 106 2 572 576 (Pubitemid 40981253)
32. Nardi M., Tomlinson S., Greco M. A., Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell: 2001; 106 5 551 561 (Pubitemid 32879317)
33. Ballem P. J., Belzberg A., Devine D. V., et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med: 1992; 327 25 1779 1784
34. Zucker-Franklin D., Seremetis S., Zheng Z. Y. Internalization of human immunodeficiency virus type I and other retroviruses by megakaryocytes and platelets. Blood: 1990; 75 10 1920 1923 (Pubitemid 20180278)
35. Stasi R., Sarpatwari A., Segal J. B., et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood: 2009; 113 6 1231 1240
36. Ryan J. M., Barry F. P., Murphy J. M., Mahon B. P. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond): 2005; 2 8
37. Aggarwal S., Pittenger M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood: 2005; 105 4 1815 1822 (Pubitemid 40223708)
38. Pérez-Simón J. A., Tabera S., Sarasquete M. E., et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy: 2009; 11 6 698 705
39. Fang B., Mai L., Li N., Song Y. Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells. Stem Cells Dev: 2012; 21 3 497 502
40. Norgaard M., Jensen A. O., Engebjerg M. C., et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood: 2011; 117 13 3514 3520
41. Cohen Y. C., Djulbegovic B., Shamai-Lubovitz O., Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med: 2000; 160 11 1630 1638 (Pubitemid 30367902)
42. Portielje J. E., Westendorp R. G., Kluin-Nelemans H. C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood: 2001; 97 9 2549 2554
43. George J. N., Woolf S. H., Raskob G. E., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood: 1996; 88 1 3 40 (Pubitemid 26230668)
44. Stasi R., Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc: 2004; 79 4 504 522 (Pubitemid 38401771)
45. Cines D. B., Bussel J. B. How I treat idiopathic thrombocytopenic purpura (ITP). Blood: 2005; 106 7 2244 2251 (Pubitemid 41510792)
46. George J. N. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost: 2006; 4 8 1664 1672 (Pubitemid 44144790)
47. Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol: 2006; 43 3 Suppl 5 S3 10; discussion S18-S19
48. Neunert C., Lim W., Crowther M., Cohen A., Solberg L. Jr, Crowther M. A.; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood: 2011; 117 16 4190 4207
49. Cheng Y., Wong R. S., Soo Y. O., et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med: 2003; 349 9 831 836 (Pubitemid 37025402)
50. Mazzucconi M. G., Fazi P., Bernasconi S., et al. Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood: 2007; 109 4 1401 1407 (Pubitemid 46239570)
51. Bae S. H., Ryoo H-M, Lee W. S., et al. High dose dexamethasone vs. conventional dose prednisolone for adults with immune thrombocytopenia: a prospective multicenter phase III trial. ASH Annual Meeting Abstracts: 2010; 116 21 3687
52. Gruppo Italiano Malattie EMatologiche dell'Adulto. Prednisone or dexamethasone in treating patients with newly diagnosed, previously untreated primary immune thrombocytopenic purpura. Available at: http://clinicaltrials. gov/ct2/show/NCT00657410. Accessed on 18 February 2012.
53. Scaradavou A., Woo B., Woloski B. M., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood: 1997; 89 8 2689 2700 (Pubitemid 27172553)
54. Newman G. C., Novoa M. V., Fodero E. M., Lesser M. L., Woloski B. M., Bussel J. B. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol: 2001; 112 4 1076 1078 (Pubitemid 32322940)
55. Meyer O., Kiesewetter H., Hermsen M., et al. Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia. Pediatr Blood Cancer: 2006; 47 5, Suppl 721 722 (Pubitemid 44360040)
56. Gaines A. R. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood: 2005; 106 5 1532 1537 (Pubitemid 41208562)
57. Ramachandran P., Li D., Muller C., et al. Potential identification of high risk populations for acute hemolytic reactions following Rh0 (D) immune globulin. ASH Annual Meeting Abstracts: 2010; 116 21 3685
58. Carr J. M., Kruskall M. S., Kaye J. A., Robinson S. H. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med: 1986; 80 6 1051 1054
59. Salama A., Kiesewetter H., Kalus U., Movassaghi K., Meyer O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost: 2008; 100 5 762 765
60. Culić S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol: 2003; 120 5 909 910 (Pubitemid 36315119)
61. Barnes C., Blanchette V., Canning P., Carcao M. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med: 2005; 15 2 145 150 (Pubitemid 40663546)
62. Busani S., Marietta M., Pasetto A., Girardis M. Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage. Thromb Haemost: 2005; 93 2 381 382 (Pubitemid 40253748)
63. Savani B. N., Dunbar C. E., Rick M. E. Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol: 2006; 81 3 218 219
64. Wróbel G., Dobaczewski G., Patkowski D., Sokół A., Grotthus E. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer: 2006; 47 5, Suppl 729 730 (Pubitemid 44360043)
65. Salama A., Rieke M., Kiesewetter H., von Depka M. Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Ann Hematol: 2009; 88 1 11 15
66. Kojouri K., Vesely S. K., Terrell D. R., George J. N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood: 2004; 104 9 2623 2634 (Pubitemid 39434940)
67. Vianelli N., Galli M., de Vivo A., et al. Gruppo Italiano per lo Studio delle Malattie Ematologiche dell'Adulto. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica: 2005; 90 1 72 77 (Pubitemid 40193756)
68. Najean Y., Rain J. D., Billotey C. The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol: 1997; 97 3 547 550 (Pubitemid 27261616)
69. Sarpatwari A., Provan D., Erqou S., Sobnack R., David Tai F. W., Newland A. C. Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. Br J Haematol: 2010; 151 5 477 487
70. Schilling R. F. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med: 1995; 122 3 187 188
71. Stasi R., Evangelista M. L., Stipa E., Buccisano F., Venditti A., Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost: 2008; 99 1 4 13
72. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood: 2001; 98 4 952 957
73. Arnold D. M., Dentali F., Crowther M. A., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med: 2007; 146 1 25 33 (Pubitemid 351650318)
74. Patel V. L., Mahevas M., Stasi R., et al. Long-term outcome following B-cell depletion therapy with rituximab in children and adults with immune thrombocytopenia (ITP). ASH Annual Meeting Abstracts: 2010; 116 21 72
75. Godeau B., Fain O., Porcher R., et al. Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective phase 2 study. Blood: 2006; 108 11 Abstract #478
76. Schipperus M., Fijnheer R. New therapeutic options for immune thrombocytopenia. Neth J Med: 2011; 69 1 480 485
77. Willis F., Marsh J. C., Bevan D. H., et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol: 2001; 114 4 891 898 (Pubitemid 32953751)
78. Cosgriff T. M., Black M. L., Stein W. III. Successful treatment of severe refractory idiopathic thrombocytopenic purpura with liposomal doxorubicin. Am J Hematol: 1998; 57 1 85 86 (Pubitemid 28047206)
79. Bernard T., Kelsey S. M., Macey M. G., Cahill M. R., Howe T., Newland A. C. Protein-A-column plasma immunoadsorption in refractory autoimmune neutropenia and thrombocytopenia. Lancet: 1993; 341 8861 1657 1658 (Pubitemid 23175266)
80. Huhn R. D., Fogarty P. F., Nakamura R., et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood: 2003; 101 1 71 77 (Pubitemid 36025889)
81. Wang B., Nichol J. L., Sullivan J. T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther: 2004; 76 6 628 638 (Pubitemid 39601552)
82. Erickson-Miller C. L., DeLorme E., Tian S. S., et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol: 2005; 33 1 85 93 (Pubitemid 40127647)
83. Kuter D. J., Bussel J. B., Lyons R. M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet: 2008; 371 9610 395 403 (Pubitemid 351181334)
84. Kuter D. J., Rummel M., Boccia R., et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med: 2010; 363 20 1889 1899
85. Kuter D. J., Bussel J. B., Newland A., et al. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): final report from an open-label extension study. ASH Annual Meeting Abstracts: 2010; 116 21 68
86. Bussel J. B., Provan D., Shamsi T., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet: 2009; 373 9664 641 648
87. Cheng G., Saleh M. N., Marcher C., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet: 2011; 377 9763 393 402
88. Stasi R., Cheng G., Saleh M. N., et al. Durable and overall platelet responses in patients with chronic idiopathic thrombocytopenic purpura (ITP) during long-term treatment with oral eltrombopag by splenectomy status: the RAISE study. Haematologica: 2009; 94 Suppl 2 Abstract 0231
89. Saleh M. N., Cheng G., Bussel J. B., et al. EXTEND study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) From June 2006 to February 2010. ASH Annual Meeting Abstracts: 2010; 116 21 67
90. Yan X. Q., Lacey D., Hill D., et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood: 1996; 88 2 402 409 (Pubitemid 26240370)
91. Kakumitsu H., Kamezaki K., Shimoda K., et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res: 2005; 29 7 761 769 (Pubitemid 40779483)
92. Villeval J. L., Cohen-Solal K., Tulliez M., et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood: 1997; 90 11 4369 4383 (Pubitemid 27508443)
93. Pecquet C., Staerk J., Chaligné R., et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood: 2010; 115 5 1037 1048
94. Teofili L., Giona F., Torti L., et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica: 2010; 95 1 65 70
95. Kuter D. J., Mufti G. J., Bain B. J., Hasserjian R. P., Davis W., Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood: 2009; 114 18 3748 3756
96. Saleh M. N., Bussel J. B., Meyer O., et al. Results of bone marrow examinations in patients with chronic immune thrombocytopenic purpura treated with eltrombopag. ASH Annual Meeting Abstracts: 2009; 114 22 1326